{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:51:04Z","timestamp":1785293464977,"version":"3.55.0"},"reference-count":141,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Kidney transplantation (KT) is the best treatment for patients with kidney failure, associated with improved survival and quality of life compared with maintenance dialysis. However, despite constant improvements in the assessment and management of the alloimmune response, KT patients frequently demonstrate a reduced estimated glomerular filtration rate. Therefore, the usual complications of chronic kidney disease (CKD), such as anemia, hypertension, metabolic acidosis, hyperkalemia, or persistent secondary hyperparathyroidism, are highly prevalent after KT. However, their underlying mechanisms are different in the transplant setting (compared with the nontransplanted CKD population), and management recommendations are based on relatively poor-quality data. In recent years, new therapies have emerged, significantly improving kidney and cardiovascular outcomes of non-KT patients with CKD. Whether those new drugs could improve the outcomes of KT patients has largely been under investigated so far. In this review, we will address the challenges of the management of a KT patient with a reduced estimated glomerular filtration rate, cover the published evidence, and highlight the critical knowledge gaps.<\/jats:p>","DOI":"10.1097\/tp.0000000000005186","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:00:31Z","timestamp":1724904031000},"page":"622-637","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Bridging the Gap Between CKD Management Paradigms in Transplant and Nontransplant Settings: Published Evidence, Challenges, and Perspectives"],"prefix":"10.1097","volume":"109","author":[{"given":"In\u00e8s","family":"Dufour","sequence":"first","affiliation":[{"name":"Department of Nephrology, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."},{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott","family":"Van Regemorter","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."},{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Kanaan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."},{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Buemi","sequence":"additional","affiliation":[{"name":"Department of Abdominal Surgery and Transplantation, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Darius","sequence":"additional","affiliation":[{"name":"Department of Abdominal Surgery and Transplantation, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Mourad","sequence":"additional","affiliation":[{"name":"Department of Abdominal Surgery and Transplantation, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Goffin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."},{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."},{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Devresse","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."},{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain, Brussels, Belgium."},{"name":"Department of Abdominal Surgery and Transplantation, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Gillion","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cliniques universitaires Saint-Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium."},{"name":"Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"R1-20250325","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"R2-20250325","doi-asserted-by":"crossref","first-page":"e1520","DOI":"10.1097\/TXD.0000000000001520","article-title":"Evolving trends in kidney transplant outcomes among older adults: a comparative analysis before and during the COVID-19 pandemic.","volume":"9","author":"Li","year":"2023","journal-title":"Transplant Direct"},{"key":"R3-20250325","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1046\/j.1600-6143.2003.00315.x","article-title":"The burden of chronic kidney disease in renal transplant recipients.","volume":"4","author":"Karthikeyan","year":"2004","journal-title":"Am J Transplant"},{"key":"R4-20250325","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1399-0012.2009.01023.x","article-title":"Prevalence and staging of chronic kidney disease in renal transplant recipients.","volume":"23","author":"Costa de Oliveira","year":"2009","journal-title":"Clin Transplant"},{"key":"R5-20250325","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.V1191735","article-title":"Explained and unexplained ischemic heart disease risk after renal transplantation.","volume":"11","author":"Kasiske","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R6-20250325","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1523-1755.1998.00744.x","article-title":"Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study.","volume":"53","author":"Opelz","year":"1998","journal-title":"Kidney Int"},{"key":"R7-20250325","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000070864","article-title":"Death with functioning graft in living donor kidney transplantation: analysis of risk factors.","volume":"23","author":"El-Agroudy","year":"2003","journal-title":"Am J Nephrol"},{"key":"R8-20250325","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"R9-20250325","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1681\/ASN.2012080777","article-title":"Angiotensin II blockade in kidney transplant recipients.","volume":"24","author":"Ibrahim","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R10-20250325","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ndt\/gfp581","article-title":"Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.","volume":"25","author":"Philipp","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R11-20250325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000357205","article-title":"Specific management of anemia and hypertension in renal transplant recipients: influence of renin-angiotensin system blockade.","volume":"39","author":"Salzberg","year":"2014","journal-title":"Am J Nephrol"},{"key":"R12-20250325","first-page":"CD003598","article-title":"Antihypertensive treatment for kidney transplant recipients.","volume":"2009","author":"Cross","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R13-20250325","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2215\/CJN.0000000000000439","article-title":"Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients (the SPIREN trial): a randomized placebo-controlled clinical trial.","volume":"19","author":"Mortensen","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"R14-20250325","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.112.196352","article-title":"Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review.","volume":"60","author":"Bullo","year":"2012","journal-title":"Hypertension"},{"key":"R15-20250325","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2215\/CJN.02560220","article-title":"Association between use of hydrochlorothiazide and risk of keratinocyte cancers in kidney transplant recipients.","volume":"15","author":"Letellier","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"R16-20250325","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00228-022-03299-x","article-title":"Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: a systematic review and meta-analysis.","volume":"78","author":"de Macedo Andrade","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-20250325","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1681\/ASN.2005090955","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.","volume":"17","author":"Heinze","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R18-20250325","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1681\/ASN.2006050543","article-title":"No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report.","volume":"17","author":"Opelz","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R19-20250325","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.ajkd.2016.08.018","article-title":"Renin-Angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials.","volume":"69","author":"Hiremath","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R20-20250325","doi-asserted-by":"crossref","first-page":"220","DOI":"10.5500\/wjt.v11.i6.220","article-title":"Post-transplant erythrocytosis after kidney transplantation: a review.","volume":"11","author":"Alzoubi","year":"2021","journal-title":"World J Transplant"},{"issue":"Suppl 3","key":"R21-20250325","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients.","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"issue":"Suppl 15","key":"R22-20250325","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1681\/ASN.V11suppl_1s1","article-title":"Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation.","volume":"11","author":"Kasiske","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R24-20250325","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000496140","article-title":"Posttransplantation anemia in kidney transplant recipients.","volume":"142","author":"Gafter-Gvili","year":"2019","journal-title":"Acta Haematol"},{"key":"R25-20250325","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/ndt\/gfn653","article-title":"Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).","volume":"24","author":"Locatelli","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R26-20250325","first-page":"100097","article-title":"Extended literature review of the role of erythropoietin stimulating agents (ESA) use in the management of post renal transplant anaemia.","volume":"7","author":"Alshamsi","year":"2022","journal-title":"Transplant Rep"},{"key":"R27-20250325","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1681\/ASN.2011060546","article-title":"Correction of postkidney transplant anemia reduces progression of allograft nephropathy.","volume":"23","author":"Choukroun","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"R28-20250325","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ndt\/gfy365","article-title":"The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial.","volume":"34","author":"Tsujita","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"R29-20250325","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/ndt\/gfaa219","article-title":"Haematological disorders following kidney transplantation.","volume":"37","author":"Malyszko","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"R30-20250325","doi-asserted-by":"crossref","first-page":"100681","DOI":"10.1016\/j.xkme.2023.100681","article-title":"Treatment options for anemia in kidney transplant patients: a review.","volume":"5","author":"Bonomini","year":"2023","journal-title":"Kidney Med"},{"key":"R31-20250325","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease.","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"R32-20250325","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"R33-20250325","first-page":"2071","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia.","volume":"2006","author":"Dru\u0308eke","year":"2084","journal-title":"N Engl J Med"},{"key":"R34-20250325","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/ki.2011.473","article-title":"Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury.","volume":"81","author":"Cassis","year":"2012","journal-title":"Kidney Int"},{"key":"R35-20250325","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses to therapy.","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"R36-20250325","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis.","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"R37-20250325","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis.","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"R38-20250325","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/ndt\/gfab318","article-title":"The ASCEND-ND trial: study design and participant characteristics.","volume":"37","author":"Perkovic","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"R39-20250325","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI84433","article-title":"Hypoxia-dependent regulation of inflammatory pathways in immune cells.","volume":"126","author":"Taylor","year":"2016","journal-title":"J Clin Invest"},{"key":"R40-20250325","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int"},{"key":"R41-20250325","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ekir.2024.04.021","article-title":"The efficacy and safety of roxadustat for the treatment of posttransplantation anemia: a randomized Study.","volume":"9","author":"Kong","year":"2024","journal-title":"Kidney Int Rep"},{"key":"R42-20250325","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1007\/s40620-023-01773-y","article-title":"Impact of thrice-weekly cotrimoxazole prophylaxis on creatinine and potassium plasma levels in kidney transplant recipients.","volume":"36","author":"Ardhe","year":"2023","journal-title":"J Nephrol"},{"key":"R43-20250325","doi-asserted-by":"crossref","first-page":"100611","DOI":"10.1016\/j.trre.2021.100611","article-title":"Management of hyperkalemia: a focus on kidney transplant recipients.","volume":"35","author":"Almalki","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"key":"R44-20250325","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gfae056","article-title":"Hyperkalemia treatment standard.","volume":"39","author":"Palmer","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"R45-20250325","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/MNH.0000000000000657","article-title":"Novel approaches to management of hyperkalaemia in kidney transplantation.","volume":"30","author":"Rizk","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R46-20250325","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40620-014-0105-9","article-title":"Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients.","volume":"27","author":"Van Ende","year":"2014","journal-title":"J Nephrol"},{"key":"R47-20250325","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1097\/TP.0000000000002829","article-title":"Safety, effectiveness, and tolerability of patiromer in kidney transplant recipients.","volume":"103","author":"Lim","year":"2019","journal-title":"Transplantation"},{"key":"R48-20250325","first-page":"e595","article-title":"Largest experience of safety, and & efficacy of patiromer in solid organ transplants (SOT).","volume":"20","author":"Singh","year":"2020","journal-title":"Am J Transplant"},{"key":"R49-20250325","doi-asserted-by":"crossref","first-page":"e13791","DOI":"10.1111\/ctr.13791","article-title":"Sodium zirconium cyclosilicate use in solid organ transplant recipients and its effect on potassium and immunosuppression.","volume":"34","author":"Winstead","year":"2020","journal-title":"Clin Transplant"},{"key":"R50-20250325","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1093\/ndt\/gfab172","article-title":"Sodium zirconium cyclosilicate use in kidney transplant recipients.","volume":"36","author":"Swanson","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"R51-20250325","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2215\/CJN.11371015","article-title":"Bone disease after kidney transplantation.","volume":"11","author":"Bouquegneau","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"R52-20250325","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/nu15010167","article-title":"Bone disease in chronic kidney disease and kidney transplant.","volume":"15","author":"Bellorin-Font","year":"2022","journal-title":"Nutrients"},{"key":"R53-20250325","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.semnephrol.2012.12.019","article-title":"Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients.","volume":"33","author":"Evenepoel","year":"2013","journal-title":"Semin Nephrol"},{"key":"R54-20250325","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00223-021-00837-0","article-title":"Bone mineral disease after kidney transplantation.","volume":"108","author":"Torregrosa","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"R55-20250325","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1097\/TP.0b013e3181a6bbda","article-title":"Risk of fractures after renal transplantation in the United States.","volume":"87","author":"Nikkel","year":"2009","journal-title":"Transplantation"},{"key":"R56-20250325","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1097\/TP.0b013e31828eead8","article-title":"Fracture risk in kidney transplant recipients: a systematic review.","volume":"95","author":"Naylor","year":"2013","journal-title":"Transplantation"},{"key":"R57-20250325","doi-asserted-by":"crossref","first-page":"100474","DOI":"10.1016\/j.xkme.2022.100474","article-title":"Kidney transplantation, immunosuppression and the risk of fracture: clinical and economic implications.","volume":"4","author":"Kuppachi","year":"2022","journal-title":"Kidney Med"},{"key":"R58-20250325","doi-asserted-by":"crossref","first-page":"863","DOI":"10.7326\/0003-4819-121-11-199412010-00007","article-title":"Bone pain in transplant recipients responsive to calcium channel blockers.","volume":"121","author":"Gauthier","year":"1994","journal-title":"Ann Intern Med"},{"key":"R59-20250325","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1993.218","article-title":"Epiphyseal impaction as a cause of severe osteoarticular pain of lower limbs after renal transplantation.","volume":"44","author":"Goffin","year":"1993","journal-title":"Kidney Int"},{"key":"R60-20250325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"R61-20250325","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/SLA.0000000000001431","article-title":"How well does renal transplantation cure hyperparathyroidism?","volume":"262","author":"Lou","year":"2015","journal-title":"Ann Surg"},{"key":"R62-20250325","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/ndt\/gfh128","article-title":"Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study.","volume":"19","author":"Evenepoel","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R63-20250325","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3390\/medicina56060302","article-title":"Risk factors and management of osteoporosis post-transplant.","volume":"56","author":"Kovvuru","year":"2020","journal-title":"Medicina (Kaunas)"},{"key":"R64-20250325","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1399-0012.2011.01524.x","article-title":"Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.","volume":"26","author":"Evenepoel","year":"2012","journal-title":"Clin Transplant"},{"key":"R65-20250325","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ekir.2024.04.004","article-title":"Etelcalcetide use during maintenance hemodialysis and incidence of parathyroidectomy after kidney transplantation.","volume":"9","author":"Delaey","year":"2024","journal-title":"Kidney Int Rep"},{"key":"R66-20250325","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000446863","article-title":"Vitamin D in kidney transplant recipients: mechanisms and therapy.","volume":"43","author":"Cianciolo","year":"2016","journal-title":"Am J Nephrol"},{"key":"R67-20250325","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11914-018-0490-4","article-title":"Mineral and bone disease in kidney transplant recipients.","volume":"16","author":"Altman","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"R68-20250325","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1681\/ASN.2013111185","article-title":"Paricalcitol for secondary hyperparathyroidism in renal transplantation.","volume":"26","author":"Trillini","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R69-20250325","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/ajt.12227","article-title":"Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial.","volume":"13","author":"Amer","year":"2013","journal-title":"Am J Transplant"},{"key":"R70-20250325","first-page":"287","article-title":"Long-term use of cinacalcet in kidney transplant recipients with hypercalcemic secondary hyperparathyroidism: a single-center prospective study.","volume":"16","author":"Zavvos","year":"2018","journal-title":"Exp Clin Transplant"},{"key":"R71-20250325","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/TP.0b013e31826c3968","article-title":"Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis.","volume":"94","author":"Cohen","year":"2012","journal-title":"Transplantation"},{"key":"R72-20250325","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/ajt.12911","article-title":"A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism.","volume":"14","author":"Evenepoel","year":"2014","journal-title":"Am J Transplant"},{"key":"R73-20250325","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13318-022-00775-8","article-title":"Physiologically-based pharmacokinetic models of CYP2D6 substrate and inhibitors nebivolol, cinacalcet and mirabegron to simulate drug-drug interactions.","volume":"47","author":"Kilford","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R74-20250325","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1681\/ASN.2015060622","article-title":"A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism.","volume":"27","author":"Cruzado","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R75-20250325","doi-asserted-by":"crossref","first-page":"473","DOI":"10.23876\/j.krcp.21.210","article-title":"Parathyroidectomy versus cinacalcet in the treatment of tertiary hyperparathyroidism after kidney transplantation: a retrospective study.","volume":"41","author":"Jung","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"R76-20250325","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1053\/j.ajkd.2022.10.001","article-title":"Persistent hyperparathyroidism: a reality calling for additional evidence.","volume":"81","author":"J\u00f8rgensen","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"R77-20250325","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.ajkd.2013.01.017","article-title":"Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the chronic renal insufficiency cohort (CRIC) study.","volume":"62","author":"Dobre","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R78-20250325","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications.","volume":"20","author":"Moranne","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R79-20250325","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"R80-20250325","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-79-3-352","article-title":"Renal tubular acidosis after kidney transplantation. Natural history and significance.","volume":"79","author":"Wilson","year":"1973","journal-title":"Ann Intern Med"},{"key":"R81-20250325","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3109\/0886022X.2010.486494","article-title":"Renal tubular acidosis in renal transplantation recipients.","volume":"32","author":"Kocyigit","year":"2010","journal-title":"Ren Fail"},{"key":"R82-20250325","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1681\/ASN.2016070793","article-title":"Metabolic acidosis and long-term clinical outcomes in kidney transplant recipients.","volume":"28","author":"Park","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R83-20250325","doi-asserted-by":"crossref","first-page":"F40","DOI":"10.1152\/ajprenal.00218.2004","article-title":"Cyclosporin A produces distal renal tubular acidosis by blocking peptidyl prolyl cis-trans isomerase activity of cyclophilin.","volume":"288","author":"Watanabe","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"R84-20250325","doi-asserted-by":"crossref","first-page":"F499","DOI":"10.1152\/ajprenal.90489.2008","article-title":"The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins.","volume":"297","author":"Mohebbi","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"R85-20250325","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1097\/TXD.0000000000000910","article-title":"Effect of sodium bicarbonate in kidney transplant recipients with chronic metabolic acidosis.","volume":"5","author":"Schulte","year":"2019","journal-title":"Transplant Direct"},{"key":"R86-20250325","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.ekir.2021.06.006","article-title":"A pilot study of the safety and efficacy of alkali therapy on vascular function in kidney transplant recipients.","volume":"6","author":"Bohling","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R87-20250325","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(22)02606-X","article-title":"Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.","volume":"401","author":"Mohebbi","year":"2023","journal-title":"Lancet"},{"key":"R88-20250325","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2215\/CJN.01100112","article-title":"Correction of metabolic acidosis with potassium citrate in renal transplant patients and its effect on bone quality.","volume":"7","author":"Starke","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"R89-20250325","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1093\/ndt\/gfad112","article-title":"SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA.","volume":"38","author":"Mark","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R90-20250325","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus.","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"R91-20250325","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R92-20250325","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"R93-20250325","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R94-20250325","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R95-20250325","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease.","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"R96-20250325","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"R97-20250325","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients.","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation"},{"key":"R98-20250325","first-page":"47","article-title":"Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: a systematic review and meta-analysis.","volume":"8","author":"Chewcharat","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"R99-20250325","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.ekir.2024.05.022","article-title":"Cardioprotective effect of SGLT2 inhibitor in diabetic kidney transplant recipients: a multicenter propensity score matched study.","volume":"9","author":"Lim","year":"2024","journal-title":"Kidney Int Rep"},{"key":"R100-20250325","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5500\/wjt.v13.i5.239","article-title":"Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients.","volume":"13","author":"Ramakrishnan","year":"2023","journal-title":"World J Transplant"},{"key":"R101-20250325","doi-asserted-by":"crossref","first-page":"1332397","DOI":"10.3389\/fneph.2024.1332397","article-title":"SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations.","volume":"4","author":"Polychronopoulou","year":"2024","journal-title":"Front Nephrol"},{"key":"R102-20250325","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus.","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"R103-20250325","doi-asserted-by":"crossref","first-page":"e0125603","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats.","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One"},{"key":"R104-20250325","first-page":"1053","article-title":"Erythrocytosis and CKD.","volume":"10","author":"Aoun","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"R105-20250325","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10157-023-02413-2","article-title":"The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances.","volume":"28","author":"Chen","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"R106-20250325","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes.","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"R107-20250325","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes.","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"R108-20250325","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R109-20250325","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nefroe.2023.09.003","article-title":"Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2 diabetes mellitus and chronic kidney disease: an approach for the nephrologist.","volume":"43","author":"Cases","year":"2023","journal-title":"Nefrologia (Engl Ed)"},{"key":"R110-20250325","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R111-20250325","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R112-20250325","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"R113-20250325","first-page":"e121","article-title":"Glucagon-like Peptide 1 receptor agonists and cardiovascular outcomes in solid organ transplant recipients with diabetes mellitus.","volume":"108","author":"Dotan","year":"2024","journal-title":"Transplantation"},{"key":"R114-20250325","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"R115-20250325","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"R116-20250325","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"R117-20250325","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"R118-20250325","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0\u2009mg of liraglutide in weight management.","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"R119-20250325","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1111\/ajt.15784","article-title":"Obesity, transplantation, and bariatric surgery: an evolving solution for a growing epidemic.","volume":"20","author":"Diwan","year":"2020","journal-title":"Am J Transplant"},{"key":"R120-20250325","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13300-018-0420-6","article-title":"Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk.","volume":"9","author":"Goncalves","year":"2018","journal-title":"Diabetes Ther"},{"key":"R121-20250325","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R122-20250325","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41581-024-00827-z","article-title":"Combination therapy for kidney disease in people with diabetes mellitus.","volume":"20","author":"van Raalte","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"R123-20250325","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present.","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol"},{"key":"R124-20250325","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary.","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int"},{"key":"R125-20250325","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.ajkd.2021.02.332","article-title":"Recipient obesity and kidney transplant outcomes: a mate-kidney analysis.","volume":"78","author":"Sureshkumar","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"R126-20250325","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0899-9007(01)00723-7","article-title":"Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients.","volume":"18","author":"Baum","year":"2002","journal-title":"Nutrition"},{"key":"R127-20250325","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/ctr.12456","article-title":"Pre-transplant predictors of one yr weight gain after kidney transplantation.","volume":"28","author":"Cashion","year":"2014","journal-title":"Clin Transplant"},{"key":"R128-20250325","doi-asserted-by":"crossref","first-page":"E484","DOI":"10.1111\/ctr.12149","article-title":"The role of diet and physical activity in post-transplant weight gain after renal transplantation.","volume":"27","author":"Zelle","year":"2013","journal-title":"Clin Transplant"},{"key":"R129-20250325","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/00365590802273226","article-title":"Determinants of short-term changes in body composition following renal transplantation.","volume":"43","author":"Dolgos","year":"2009","journal-title":"Scand J Urol Nephrol"},{"key":"R130-20250325","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-6143.2007.02057.x","article-title":"A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients.","volume":"8","author":"Vincenti","year":"2008","journal-title":"Am J Transplant"},{"key":"R131-20250325","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.jrn.2008.11.006","article-title":"Higher levels of physical activity are associated with a lower risk of abnormal glucose tolerance in renal transplant recipients.","volume":"19","author":"Orazio","year":"2009","journal-title":"J Ren Nutr"},{"key":"R132-20250325","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1016\/j.transproceed.2005.10.069","article-title":"Obesity in renal transplantation: analysis of 2691 patients.","volume":"37","author":"Cofan","year":"2005","journal-title":"Transplant Proc"},{"key":"R133-20250325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.jrn.2013.09.002","article-title":"Obesity in kidney transplantation.","volume":"24","author":"Chan","year":"2014","journal-title":"J Ren Nutr"},{"key":"R134-20250325","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/TP.0b013e3182100f3a","article-title":"Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up.","volume":"91","author":"Hoogeveen","year":"2011","journal-title":"Transplantation"},{"key":"R135-20250325","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/j.1600-6143.2005.01104.x","article-title":"One-year post-transplant weight gain is a risk factor for graft loss.","volume":"5","author":"Ducloux","year":"2005","journal-title":"Am J Transplant"},{"key":"R136-20250325","doi-asserted-by":"crossref","first-page":"155","DOI":"10.6002\/ect.2017.0305","article-title":"Effects of a structured physical activity program on habitual physical activity and body composition in patients with chronic kidney disease and in kidney transplant recipients.","volume":"17","author":"Masajtis-Zagajewska","year":"2019","journal-title":"Exp Clin Transplant"},{"key":"R137-20250325","first-page":"250","article-title":"Effect of regular physical activity and lifestyle changes on insulin resistance in patients after kidney transplantation.","volume":"125","author":"Granak","year":"2024","journal-title":"Bratisl Lek Listy"},{"key":"R138-20250325","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2215\/CJN.03340410","article-title":"Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients.","volume":"6","author":"Zelle","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R139-20250325","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1249\/MSS.0000000000001886","article-title":"Physical activity and cardiovascular risk among kidney transplant patients.","volume":"51","author":"Kang","year":"2019","journal-title":"Med Sci Sports Exerc"},{"key":"R140-20250325","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.ekir.2021.04.009","article-title":"A narrative review of dietary approaches for kidney transplant patients.","volume":"6","author":"Goldfarb Cyrino","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R141-20250325","doi-asserted-by":"crossref","first-page":"e000283","DOI":"10.1136\/bmjdrc-2016-000283","article-title":"Mediterranean style diet is associated with low risk of new-onset diabetes after renal transplantation.","volume":"5","author":"Oste","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"key":"R142-20250325","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2215\/CJN.06710619","article-title":"Mediterranean style diet and kidney function loss in kidney transplant recipients.","volume":"15","author":"Gomes-Neto","year":"2020","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T07:37:28Z","timestamp":1743147448000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":141,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005186","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]}}}